迪哲医药两款源头创新产品将亮相ASCO 构筑血液瘤与肺癌领域全球竞争新优势

Core Viewpoint - Dizh Medical (688192) announced that its two innovative products, DZD8586 and DZD6008, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, highlighting the company's competitive advantages in the fields of hematological malignancies and lung cancer [1] Group 1: DZD8586 in B-NHL and CLL/SLL - DZD8586 is expected to provide a new treatment option for patients with B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2] - A summary analysis of a Phase I/II clinical study involving 51 patients with relapsed/refractory CLL/SLL showed an objective response rate (ORR) of 84.2% at a recommended dose of 50mg, indicating good anti-tumor efficacy and manageable safety [2] - DZD8586 also demonstrated anti-tumor activity in a Phase II study for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with promising results to be presented at the 2025 European Hematology Association (EHA) annual meeting [2][3] Group 2: DZD6008 in NSCLC - DZD6008 is anticipated to address unmet clinical needs in non-small cell lung cancer (NSCLC), particularly for patients with EGFR mutations who have undergone multiple lines of treatment [4] - Early clinical data from the TIAN-SHAN2 study showed that 83.3% of 12 patients with advanced NSCLC experienced tumor shrinkage after treatment with DZD6008, demonstrating durable anti-tumor activity and good tolerability [4][5] - DZD6008 exhibits excellent blood-brain barrier penetration, with a concentration ratio in cerebrospinal fluid exceeding 1, indicating its potential effectiveness in patients with brain metastases [4][5] Group 3: Company Strategy and Future Outlook - The founder and CEO of Dizh Medical emphasized the company's commitment to accelerating the global development of DZD8586 and DZD6008, aiming to provide more treatment options for patients with B-NHL and NSCLC [6] - The promising clinical data presented at ASCO reinforces the company's confidence in advancing DZD8586 into Phase III clinical trials [6]